Combination antiretroviral therapy (cART) can reduce HIV-1 viremia to clinically undetectable levels. However, replication competent virus persists in a long-lived latent reservoir n resting, memory CD4+ T cells. The latent reservoir in resting CD4+ T cells is the major barrier to curing HIV-1 infection. The recent case of the Berlin patient has suggested that it may be possible to cure HIV-1 infection in certain situations. As efforts to cure HIV-1 infection progress, it will become critical to measure the latent reservoir in patients participating in clinical trials of eradication strategies. Our laboratory has developed a limiting dilution virus outgrowth assay that can be used to demonstrate the presence and persistence of latent HIV-1 in patients. Here we describe both the original and a simplified version of the quantitative virus outgrowth assay (QVOA) to measure the frequency of latently infected resting CD4+ T cells with replication competent provirus in patients on suppressive cART.
CITATION STYLE
Laird, G. M., Rosenbloom, D. I. S., Lai, J., Siliciano, R. F., & Siliciano, J. D. (2016). Measuring the frequency of latent HIV-1 in resting CD4+ T cells using a limiting dilution coculture assay. In Methods in Molecular Biology (Vol. 1354, pp. 239–253). Humana Press Inc. https://doi.org/10.1007/978-1-4939-3046-3_16
Mendeley helps you to discover research relevant for your work.